Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ceftazidime. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 4/20 | 1.00 |
| ▸ | ESR1 | P03372 | 3/20 | 1.00 |
| ▸ | PPARG | P37231 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.99 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.99 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | APEX1 | P27695 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | RECQL | P46063 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ceftazidime SCHEMBL27816764 | 1.00 | NR1I2 (1.00) | NR1I2ESR1PPARGPGRTDP1 | |
| Ceftazidime SCHEMBL10746412 | 1.00 | NR1I2 (1.00) | NR1I2ESR1PPARGPGRTDP1 | |
| Ceftazidime SCHEMBL10746421 | 1.00 | NR1I2 (1.00) | NR1I2ESR1PPARGPGRTDP1 | |
| Ceftazidime SCHEMBL10678530 | 1.00 | NR1I2 (1.00) | NR1I2ESR1PPARGPGRTDP1 | |
| Ceftazidime SCHEMBL36850 | 1.00 | NR1I2 (1.00) | NR1I2ESR1PPARGPGRTDP1 | |
| Ceftazidime SCHEMBL1625852 | 1.00 | NR1I2 (1.00) | NR1I2ESR1PPARGPGRTDP1 | |
| Ceftazidime SCHEMBL23175189 | 0.99 | TDP1 (1.00) | NR1I2ESR1PPARGPGRTDP1 | |
| Ceftazidime SCHEMBL7666202 | 0.99 | NR1I2 (0.99) | NR1I2ESR1PPARGPGRTDP1 | |
| Ceftazidime SCHEMBL20603074 | 0.99 | NR1I2 (0.99) | NR1I2ESR1PPARGPGRTDP1 | |
| Ceftazidime SCHEMBL9664455 | 0.99 | NR1I2 (0.99) | NR1I2ESR1PPARGPGRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 38704 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075499-A | Ceftazidime avibactam sodium intermediate product for injection and preparation method thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-12637481-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2026-05-26 | — | — | US | claimed |
| CN-122084788-A | Ceftazidime and method for determining preparation polymer thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-117305079-B | Method for detecting drug resistance heterogeneity of bacteria based on single-cell microfluidic system and application thereof | 天津现代创新中药科技有限公司 | 2026-05-22 | — | — | CN | claimed |
| WO-2026107113-A1 | MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF | CALIDI BIOTHERAPEUTICS (NEVADA), INC. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026104587-A1 | CYCLIC BORONIC ACID ESTERS USEFUL AS ADJUVANTS IN THE TREATMENT OF BACTERIAL INFECTIONS | ADJUTEC PHARMA AS (NO) | 2026-05-21 | — | — | WO | claimed |
| US-20260137558-A1 | OPHTHALMIC DEVICE | Able Tx Ltd. (IL) | 2026-05-21 | — | — | US | claimed |
| WO-2026106551-A1 | ANTIMICROBIAL PEPTIDE NANONETS AND METHODS OF USE THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2026-05-21 | — | — | WO | claimed |
| US-12631653-B2 | Methods for diagnosing and treating uveitis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-19 | — | — | US | claimed |
| CN-115215923-B | Macrocyclic broad-spectrum antibiotics | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | claimed |
| EP-0134302-A1 | Pharmaceutical compositions for treating resistant bacteria including anaerobes | Bristol-Myers Company (US) | 1985-03-20 | — | — | EP | claimed |
| US-4503040-A | 6-(Aminoacyloxymethyl)penicillanic acid 1,1-dioxides as beta-lactamase inhibitors | PFIZER INC. (US) | 1985-03-05 | — | — | US | claimed |
| EP-0113568-A2 | Intermediates for the preparation of ceftazidine, and process for their preparation | ELI LILLY AND COMPANY (US) | 1984-07-18 | — | — | EP | claimed |
| US-4452796-A | ANTIBIOTICS | PFIZER INC. (US) | 1984-06-05 | — | — | US | claimed |
| US-4427678-A | 6-Aminomethylpenicillanic acid 1,1-dioxide derivatives as beta-lactamase inhibitors | PFIZER INC. (US) | 1984-01-24 | — | — | US | claimed |
| US-4406887-A | PENICILLINS AND CEPHALOSPORIN MIXTURES | BRISTOL-MYERS COMPANY (US) | 1983-09-27 | — | — | US | claimed |
| EP-0088847-A1 | Thiazole derivatives and their use in the manufacture of beta-lactam antibiotics | GLAXO GROUP LIMITED (GB) | 1983-09-21 | — | — | EP | claimed |
| EP-0084925-A1 | 6-Aminoalkylpenicillanic acid 1,1-dioxides and derivatives as beta-lactamase inhibitors | PFIZER INC. (US) | 1983-08-03 | — | — | EP | claimed |
| WO-1982003090-A1 | METHOD AND KIT FOR IDENTIFICATION OF BETA-LACTAMASES | JAMES RICHARD | 1982-09-16 | — | — | WO | claimed |
| EP-0059645-A1 | Method and kit for identification of beta-lactamases | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1982-09-08 | — | — | EP | claimed |